Manufacturing Perspectives: Lessons for Biomanufacturing from Small-Molecule Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Perspectives: Lessons for Biomanufacturing from Small-Molecule Manufacturing
A perspective from Pfizer on the lessons from small-molecule manufacturing that can be applied to biomanufacturing.


Pharmaceutical Technology
Volume 35, pp. s6-s8

Lessons from small-molecule manufacturing

The biotechnology industry has learned many good lessons as biomanufacturing has matured during the past 30 years, but there are still important lessons to be learned. Biomanufacturing would be well served to take some guidance from its older, traditional small-molecule cousin. With more than 100 years of history to its credit, traditional small-molecule pharmaceutical manufacturing has undergone its own transformational journey. Challenges in capacity, cost, quality, and compliance have required new technological and organizational solutions. Today's small-molecule supply chains would be unrecognizable to those working in the industry 50 years ago.

Of the many valuable small-molecule learnings, three are of particular interest and warrant closer examination by biomanufacturing organizations. These lessons include the small-molecule perspectives on achieving process understanding and control, embedding operational excellence principles, and driving organizational and cultural transformation.

Process understanding and control. Variability is the primary enemy of manufacturing, so strategies to understand and minimize its effect are crucial for any manufacturing unit. Small molecule-manufacturing has achieved significant progress in this area. Total quality tools, statistical methodologies, and quality risk management are regularly applied to identify, minimize, and eliminate process variability and improve product quality. Process analytical technology (PAT) is particularly important in this regard

PAT has been applied in small-molecule manufacturing for decades. In some cases, energetic PAT scientists wanted to measure everything possible and later determine what data was meaningful. This approach was often costly and burdensome to operating sites and negatively affected their enthusiasm for PAT applications. Over time, PAT advocates and operational managers aligned around identifying parameters that contribute to process understanding and ultimately to a control strategy that reduces process variability. This focus on improved process performance is consistent with lean-manufacturing principals (e.g., fewer results out of specification, increased yields, and reduced cycle times).

Highly capable processes can take advantage of real-time-release with associated benefits in reduced testing and inventory. Biomanufacturing processes can benefit from this small-molecule experience. The first goal of PAT should be process understanding, and much of this knowledge can be gained at laboratory and pilot scale. Biomanufacturing systems are typically more complex than small molecules, and analytical techniques are more specialized, thereby making it even more important to identify the critical parameters and understand their relationship to quality and productivity outputs before implementing production at commercial scale.

Another important small-molecule lesson, aligning with process understanding and control, has been the use of standardized platforms throughout development and commercialization. This approach avoids having to re-engineer the hardware part of an application for each process although method capability and calibration will be process-specific. Applying a standardized platform strategy for technology and operations in biomanufacturing will transform the current business model by increasing speed-to-market, facility flexibility and manufacturing capacity and by lowering cost structures and capital investments.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here